Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.11
ACOR's Cash to Debt is ranked higher than
65% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. ACOR: 2.11 )
ACOR' s 10-Year Cash to Debt Range
Min: 0.94   Max: No Debt
Current: 2.11

Equity to Asset 0.53
ACOR's Equity to Asset is ranked higher than
65% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ACOR: 0.53 )
ACOR' s 10-Year Equity to Asset Range
Min: -3.98   Max: 0.75
Current: 0.53

-3.98
0.75
Interest Coverage 13.99
ACOR's Interest Coverage is ranked higher than
53% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 13.99 )
ACOR' s 10-Year Interest Coverage Range
Min: 9.82   Max: 13.99
Current: 13.99

9.82
13.99
F-Score: 4
Z-Score: 2.62
M-Score: -3.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.84
ACOR's Operating margin (%) is ranked higher than
88% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. ACOR: 10.84 )
ACOR' s 10-Year Operating margin (%) Range
Min: -9345.93   Max: 12
Current: 10.84

-9345.93
12
Net-margin (%) 5.37
ACOR's Net-margin (%) is ranked higher than
85% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. ACOR: 5.37 )
ACOR' s 10-Year Net-margin (%) Range
Min: -9340.5   Max: 50.67
Current: 5.37

-9340.5
50.67
ROE (%) 3.81
ACOR's ROE (%) is ranked higher than
85% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. ACOR: 3.81 )
ACOR' s 10-Year ROE (%) Range
Min: -128.66   Max: 40.15
Current: 3.81

-128.66
40.15
ROA (%) 2.02
ACOR's ROA (%) is ranked higher than
85% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. ACOR: 2.02 )
ACOR' s 10-Year ROA (%) Range
Min: -144.41   Max: 27.41
Current: 2.02

-144.41
27.41
ROC (Joel Greenblatt) (%) 243.41
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. ACOR: 243.41 )
ACOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4297.04   Max: 908.61
Current: 243.41

-4297.04
908.61
Revenue Growth (%) 17.50
ACOR's Revenue Growth (%) is ranked higher than
89% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ACOR: 17.50 )
ACOR' s 10-Year Revenue Growth (%) Range
Min: -61.8   Max: 136.8
Current: 17.5

-61.8
136.8
» ACOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ACOR Guru Trades in Q3 2013

Paul Tudor Jones 7,700 sh (+4.05%)
Steven Cohen 84,913 sh (-66.89%)
» More
Q4 2013

ACOR Guru Trades in Q4 2013

David Dreman 1,025 sh (New)
Jim Simons 250,400 sh (New)
Paul Tudor Jones 17,000 sh (+120.78%)
Steven Cohen 44,981 sh (-47.03%)
» More
Q1 2014

ACOR Guru Trades in Q1 2014

Steven Cohen 370,900 sh (+724.57%)
David Dreman 1,526 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 217,561 sh (-13.11%)
» More
Q2 2014

ACOR Guru Trades in Q2 2014

Joel Greenblatt 51,262 sh (New)
Steven Cohen 615,600 sh (unchged)
David Dreman Sold Out
Jim Simons 41,500 sh (-80.92%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.02%$29.69 - $38.89 $ 29.98-12%51262
David Dreman 2014-06-30 Sold Out $29.69 - $38.89 $ 29.98-12%0
David Dreman 2014-03-31 Add 48.88%$27.88 - $39.43 $ 29.98-10%1526
David Dreman 2013-12-31 New Buy$28.89 - $36.54 $ 29.98-8%1025
Joel Greenblatt 2012-12-31 Sold Out 0.02%$22.48 - $26.93 $ 29.9822%0
Joel Greenblatt 2012-06-30 New Buy0.02%$21.61 - $27.02 $ 29.9826%9329
John Burbank 2012-03-31 Sold Out 0.21%$24.85 - $27.49 $ 29.9824%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 65.60
ACOR's P/E(ttm) is ranked higher than
88% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 65.60 )
ACOR' s 10-Year P/E(ttm) Range
Min: 6.35   Max: 161.37
Current: 65.6

6.35
161.37
P/B 2.50
ACOR's P/B is ranked higher than
87% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. ACOR: 2.50 )
ACOR' s 10-Year P/B Range
Min: 2.37   Max: 44.88
Current: 2.5

2.37
44.88
P/S 3.56
ACOR's P/S is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. ACOR: 3.56 )
ACOR' s 10-Year P/S Range
Min: 0.12   Max: 24.53
Current: 3.56

0.12
24.53
PFCF 22.54
ACOR's PFCF is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 22.54 )
ACOR' s 10-Year PFCF Range
Min: 10.97   Max: 130.85
Current: 22.54

10.97
130.85
EV-to-EBIT 25.48
ACOR's EV-to-EBIT is ranked higher than
91% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 25.48 )
ACOR' s 10-Year EV-to-EBIT Range
Min: 13   Max: 93.5
Current: 25.48

13
93.5
Shiller P/E 141.51
ACOR's Shiller P/E is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 141.51 )
ACOR' s 10-Year Shiller P/E Range
Min: 135.48   Max: 426.56
Current: 141.51

135.48
426.56
Current Ratio 7.33
ACOR's Current Ratio is ranked higher than
84% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. ACOR: 7.33 )
ACOR' s 10-Year Current Ratio Range
Min: 0.59   Max: 7.89
Current: 7.33

0.59
7.89
Quick Ratio 6.99
ACOR's Quick Ratio is ranked higher than
85% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. ACOR: 6.99 )
ACOR' s 10-Year Quick Ratio Range
Min: 0.42   Max: 7.89
Current: 6.99

0.42
7.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.67
ACOR's Price/Net Cash is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. ACOR: 7.67 )
ACOR' s 10-Year Price/Net Cash Range
Min: 4.51   Max: 67.12
Current: 7.67

4.51
67.12
Price/Net Current Asset Value 6.27
ACOR's Price/Net Current Asset Value is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. ACOR: 6.27 )
ACOR' s 10-Year Price/Net Current Asset Value Range
Min: 4.34   Max: 19.66
Current: 6.27

4.34
19.66
Price/Tangible Book 2.58
ACOR's Price/Tangible Book is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. ACOR: 2.58 )
ACOR' s 10-Year Price/Tangible Book Range
Min: 2.63   Max: 129.47
Current: 2.58

2.63
129.47
Price/DCF (Projected) 1.78
ACOR's Price/DCF (Projected) is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 1.78 )
ACOR' s 10-Year Price/DCF (Projected) Range
Min: 2.01   Max: 22.28
Current: 1.78

2.01
22.28
Price/Median PS Value 0.73
ACOR's Price/Median PS Value is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. ACOR: 0.73 )
ACOR' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 4.48
Current: 0.73

0.03
4.48
Price/Graham Number 2.74
ACOR's Price/Graham Number is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACOR: 2.74 )
ACOR' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 5.74
Current: 2.74

0.86
5.74
Earnings Yield (Greenblatt) 3.90
ACOR's Earnings Yield (Greenblatt) is ranked higher than
72% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ACOR: 3.90 )
ACOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 7.7
Current: 3.9

1.1
7.7
Forward Rate of Return (Yacktman) 1.37
ACOR's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. ACOR: 1.37 )
ACOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -93.5   Max: 1.7
Current: 1.37

-93.5
1.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany
Acorda Therapeutics, Inc. was incorporated in 1995 as a Delaware corporation. It is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The Company is managed and operated as one business. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec, under a license and collaboration agreement that it entered into in June 2009. It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. On February 6, 2012, it launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules, under its agreement with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc., following the launch by Apotex, Inc. of its generic tizanidine hydrochloride capsules. It is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
» More Articles for ACOR

Headlines

Articles On GuruFocus.com
Fv 58 MSN 10 Apr 19 2013 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 12,000 Shares Mar 12 2010 

More From Our Partners
Events for the Week of Sept. 8-12 Sep 10 2014 - BENZINGA

More From Other Websites
Nasdaq stocks posting largest percentage decreases Sep 15 2014
Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on... Sep 10 2014
Acorda Therapeutics to Present at the Aegis Capital 2014 Healthcare and Technology Conference Sep 04 2014
Acorda Therapeutics to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2014
Acorda Therapeutics to Present at the Baird 2014 Healthcare Conference Aug 27 2014
6 Biotech Stocks to Buy Now With Up to 100% Upside Potential Aug 20 2014
ACORDA THERAPEUTICS INC Financials Aug 15 2014
ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
Acorda Beats on Q2 Earnings & Revenues, Maintains View Aug 04 2014
Q2 2014 Acorda Therapeutics, Inc. Earnings Release - Before Market Open Jul 31 2014
ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
Acorda Therapeutics Reports Second Quarter 2014 Financial Results Jul 31 2014
Acorda Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results on July... Jul 24 2014
Acorda Therapeutics Sues Mylan Over Plan to Copy MS Drug Jul 17 2014
Actavis Fuels Growth With Acquisitions, New Generics Jul 14 2014
[video] Acorda 'firmly on the side of research': CEO Jul 10 2014
Markets Edge Higher; Alcoa Profit Beats Street View Jul 09 2014
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events Jul 09 2014
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 26 2014
Acorda's multiple sclerosis drug faces generic threat Jun 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK